Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Long-Term Investments (2022 - 2023)

Historic Long-Term Investments for Gain Therapeutics (GANX) over the last 2 years, with Q1 2023 value amounting to $988388.0.

  • Gain Therapeutics' Long-Term Investments changed N/A to $988388.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $988388.0, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2022, which is N/A changed from last year.
  • Latest data reveals that Gain Therapeutics reported Long-Term Investments of $988388.0 as of Q1 2023.
  • Gain Therapeutics' 5-year Long-Term Investments high stood at $4.9 million for Q2 2022, and its period low was $988388.0 during Q1 2023.